Investments
1
Want to inform investors similar to Andreas Schreiner about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Andreas Schreiner News
Apr 6, 2021
During the 60-minute webinar, Andreas Schreiner, MD, Vice President, Medical Affairs Neuroscience and Analgesia; and Hanna Wide, MS, Executive Director, Cell and Gene Therapy, will discuss alternate gene therapies such as opto- and chemogenetics and novel genome-editing technology as well as the use of engineered, non-replicating viral vectors, predominantly recombinant adeno-associated virus or lentivirus. Attendees will learn how to meet the requirements for surgical techniques and equipment when performing intra-CNS administration of viral vectors and operational considerations for Parkinson’s disease gene therapy studies, according to a media release from Xtalks. The free webinar will take place Wednesday, April 14, 2021 at 11am EDT (4pm BST/UK). For more information and to register, visit Xtalks .
Andreas Schreiner Investments
1 Investments
Andreas Schreiner has made 1 investments. Their latest investment was in ChargeX as part of their Angel on January 1, 2019.
Andreas Schreiner Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
1/10/2019 | Angel | ChargeX | Yes | Alexander Grots, Andreas Schreiner, Martin Heubeck, Matthias Willenbacher, Thomas Klug, and Undisclosed Angel Investors | 3 |
Date | 1/10/2019 |
|---|---|
Round | Angel |
Company | ChargeX |
Amount | |
New? | Yes |
Co-Investors | Alexander Grots, Andreas Schreiner, Martin Heubeck, Matthias Willenbacher, Thomas Klug, and Undisclosed Angel Investors |
Sources | 3 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
